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Introduction. Octogenarians are at increased risk for complications after lung resection. With alternatives such as radiation,
understanding the risks of surgery and associated survival are valuable. Data grading the severity of complications and longterm survival in this population is lacking. We reviewed our experience with lobectomy in octogenarians, grading complications
using a validated thoracic morbidity and mortality schema. Methods. We retrospectively reviewed consecutive patients aged ≥80
undergoing lobectomy between 2004 and 2012. Demographics, clinical/pathologic stage, complications, recurrence, and mortality
were collected. Complications were graded by the Seely thoracic morbidity and mortality model. Results. 45 patients (mean age
82.2 years) were analyzed. The majority of patients (28/45, 62%) were clinical stage IA/IB. 62% (28/45) of patients experienced a
complication. Only 15.6% (7/45) were considered significantly morbid (≥ grade IIIB) per the Seely model. Perioperative mortality
was 2% and half of patients were living at a follow-up of 53 months. Overall five-year survival was 52%. Conclusions. In carefully
selected octogenarians, lobectomy carries a 15.6% rate of significantly morbid complications with encouraging overall survival.
These data provide the basis for a more complete discussion with patients regarding lobectomy for lung cancer.

1. Introduction
Due to the high incidence of lung cancer in octogenarians, surgeons are increasingly confronted with the clinical challenge of how best to treat these patients with
resectable lung cancer. Fourteen percent of patients diagnosed with lung cancer in the United States from 1988–2003
were ≥80 years old [1] with the peak incidence occurring
between ages 75–79 [2]. With the general population living
longer and the baby boomer generation reaching this age
bracket in the next decade, it is imperative that we better
understand complications and survival in this growing age
group.
Making optimal treatment recommendations can be challenging for treating physicians as octogenarians in general
have more comorbidities and a worse performance status

than the younger population. While the gold standard surgical therapy for early stage lung cancer remains anatomic
resection [3], physicians may be hesitant to refer these
patients for surgical evaluation and other treatment options
including stereotactic body radiation therapy (SBRT) and
wedge resection may be suggested [4]. Currently, long-term
survival data for SBRT are limited and show a wide range
of survival ranging from a 3-year survival of 42% for stage
I [5] to 83% for stage IA [6] (see Table 4). In addition, the
surgical literature regarding octogenarians with lung cancer
is diverse and often includes patients with a wide variety
of clinical stages and resections (i.e., wedge, lobectomy, and
pneumonectomy). As a result, broad 5-year survival rates
ranging from 18.2% to 69.6% [7–17] have been reported which
are likely strongly related to variable inclusion data and extent
of resection (see Table 3).
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Prior publications have documented that octogenarians
experience higher complication rates after lung resection
which ranges from 8.4 to 68.8% [7–14, 16–19]. Data regarding
the severity, morbidity, or impact of those complications has
yet to be elucidated using a standardized validated system,
leaving physicians with an incomplete understanding of
assessing short-term surgical risks versus long-term benefit.
Furthermore, surgeons lack the data that allow them to
characterize morbidity and complications beyond “major or
minor” when counseling their patients. In order to reconcile
this, the Seely morbidity and mortality schema was designed
for application to thoracic surgical patients [20]. It provides
a standardized and validated framework for physicians to
describe complications based on the level of intervention
required [20].
Defining complication severity is important in the overeighty population to allow for accurate patient counseling
regarding surgical outcomes and to guide surgical treatment
algorithms. We sought to gain further understanding of the
inherent morbidity assumed by an octogenarian deemed
appropriate for lobectomy and to characterize complications
based on a validated thoracic surgery schema. Furthermore,
we assessed long-term survival to contextualize more completely short-term risks versus long-term survival.

2. Methods
We performed a single center retrospective review of consecutive patients aged eighty or greater who underwent
lobectomy approached by thoracotomy, video assisted thoracoscopic surgery (VATS), or robotic assisted methods
between 2004 and 2012. All patients were staged according
to the American Joint Committee on Cancer (AJCC) 7th
edition guidelines [21]. The Institutional Review Board (IRB)
approved the study and data was entered into a secure
database. Individual patient consent was waived due to the
retrospective nature of the study.
Key data elements included age, gender, body mass
index (BMI), comorbidities, percent of predicted forced
expiratory volume expired in 1 second (FEV1), percent of
predicted diffusion capacity of carbon dioxide (DLCO),
operative approach, conversion of minimally invasive operative approach to thoracotomy, mean operative time, mean
estimated blood loss, intraoperative mortality, complications,
intensive care unit (ICU) stay, clinical and pathologic stage,
procedure performed, hospital length of stay (LOS), posthospital patient disposition to home or skilled nursing facility
(SNF), follow-up duration, disease recurrence, patient status
(living or deceased), and cause of death if applicable.
Patients were staged as follows. Cross sectional imaging
was used to determine tumor size and clinical T stage (cT).
Clinical node negative status (cN0) was determined if the
patient had a standardized uptake value (SUV) <1.5 on
positron emission tomography (PET), a biopsy of a PET
positive node that was ultimately pathologically benign, or
biopsy of lymph node(s) > 1 cm in largest diameter that was
pathologically benign.
Each attending surgeon determined patient operability based on the patient’s preoperative imaging, medical
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comorbidities, activity tolerance, pulmonary function testing, and nutrition status. Specifically, this included patients
with an ECOG score of 0 or 1, a FEV1 and DLCO > 40%
predicted after lobectomy, and no anginal symptoms. Patients
with a significant cardiac history or questionable cardiac
reserve were referred to their cardiologist or newly evaluated
for clearance to tolerate a surgery and general anesthetic.
Each patient performed an in-office stair walk where heart
rate and oxygen saturation were recorded while walking at
least two flights of stairs. Patients who became significantly
dyspneic or had an oxygen saturation less than 92% while
walking two flights were considered inoperable. No comorbidity precluded consideration for an operation; however,
care was taken to optimize these conditions (i.e., blood
glucose and pulmonary function) prior to consideration of
surgery. This assessment determined the ability of a patient
to tolerate general anesthetic and a lobectomy through any
modality. Once operability was determined, the decision to
proceed with a thoracotomy or minimally invasive (VATS or
robotic) procedure was at the surgeon’s discretion.
We employed the Seely classification system, which
characterizes complication severity based on the need for
general anesthesia separating minor from major complications. Grade I complications include any complication not
requiring intervention; grade II complications include any
complication requiring pharmacologic intervention; grade
IIIA complications include any intervention not requiring
general anesthesia. Major complications were defined as
grade IIIB (any complication requiring general anesthesia),
grade IV (any complication requiring ICU admission, single
organ failure, or reintubation), and grade V (complications
leading to death) (see Table 2).
Clinical follow-up was calculated from the date of discharge to the last clinic visit. In cases where a patient was
lost to follow-up, status was verified by using the social
security death registry and/or by contacting their primary
care physician. Survival data was analyzed by the KaplanMeier method. A univariate analysis was performed to identify factors that influence overall survival including medical
comorbidities, clinical and pathologic stages, tumor size, and
complications (all and severe ≥IIIB). Statistical analyses were
completed using SPSS 18.

3. Results
A total of 45 (male = 23) patients underwent lobectomy.
No patients received neoadjuvant therapy prior to resection.
The most common comorbidity was hypertension (56%) (see
Table 1). All patients were high functioning with an ECOG of
0 (39/45, 86.7%) and 1 (6/45, 13.3%). The majority of patients
(42/45, 93.3%) underwent preoperative cardiac evaluation
by a cardiologist. Nearly all patients were clinically staged
with a diagnostic chest CT and PET. Thirty-nine patients
(86.7%) underwent preoperative cervical mediastinoscopy.
Clinical staging information was available for 41/45 patients.
Of these, 20 were stage IA (51%), 8 stage IB (21%), 5
stage IIA (11%), 1 stage IIB (2.2%), and 5 stage IIIA (11%).
Two patients underwent lobectomies for metastasectomy,
and staging information was unavailable for the remaining
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Table 1: Patient demographics.
Mean age (range)
Mean BMI (range)
Mean FEV1% predicted (range)
Mean DLCO% predicted (range)
Tobacco history: 𝑛 (%)
Mean pack years
Comorbidities: 𝑛 (%)
HTN
CAD
COPD
Prior CT surgery
Atrial fibrillation
Diabetes
Renal disease
Steroid dependent

82.2 (80–89)
25 (17–43)
86 (43–123)
71 (42–110)
39 (87%)
30
25 (56%)
14 (31%)
12 (27%)
12 (27%)
10 (22%)
3 (7%)
1 (2%)
1 (2%)

BMI: body mass index, FEV1: forced expiratory volume at one second,
DLCO: diffusing capacity for lung for carbon monoxide, HTN: hypertension,
CAD: coronary artery disease, CT: cardiothoracic, and COPD: chronic
obstructive pulmonary disease.

four patients. All patients undergoing lobectomy for lung
cancer were clinically node negative and without evidence of
metastasis (cN0 and cM0) prior to resection.
Thoracotomy was performed most commonly (27/45,
60.0%) followed by VATS (12/45, 26.7%) and robotic assisted
(3/45, 6.7%). In two cases (2/15, 13.3%), a minimally invasive
approach was converted to thoracotomy. Mean operative
time was 228 minutes (range 106–381 minutes) and mean
estimated blood loss was 50 mL. There was no intraoperative
mortality. Disposition data was available for 32/45 patients
and 27/32 (84.4%) were admitted to the ICU postoperatively.
The average ICU LOS was 3 days (range 1–13).
The pathology for most patients was non-small-cell lung
cancer (NSCLC) (39/45, 86.7%) and the majority of these
were adenocarcinoma (26/39, 66.7%). Two patients had
metastatic disease from an extrathoracic source (colorectal
and uterine stromal cell carcinoma) and 2 patients had a
spindle cell neoplasm (one bronchioloalveolar carcinoma and
one neuroendocrine tumor). In keeping with the early clinical
stage of this population, the most common pathologic stage
in the NSCLC patients was IB (13/39, 33.3%). Ten patients
(10/39, 25.6%) were IA; 3 patients were IIA (3/39, 7.7%); 3
patients were IIB (3/39, 7.7%); 7 patients were IIIA (7/39, 18%);
1 patient was IIIB (1/39, 2.6%), and 2 patients were Stage IV
(2/39, 5.1%) on final pathology.
Minor complications (grades I–IIIA) occurred in 46.7%
(21/45) of patients. New onset atrial fibrillation requiring
medical therapy was the most common complication (22.2%,
10/45). Ten patients (22.2%) had a prolonged air leak or fluid
collection that necessitated chest tube for > 5 days. Nine of
these air leaks resolved while the patient was in hospital, but
1 patient was discharged home with a chest tube due to a
persistent leak. Four patients (8.9%) were discharged from the
hospital with supplemental oxygen therapy per nasal cannula.
Severe postoperative complications (≥IIIB) occurred in
15.6% (7/45) of patients. Three patients (6.7%) developed

pneumonia requiring ICU care. Two patients (4.4%) required
return to the operating room for control of postoperative
hemorrhage within twenty-four hours of the initial operation. Additional severe complications included myocardial
infarction (2/45, 4.4%) and one inpatient sustained an ankle
fracture due to a fall, which subsequently required operative
fixation (see Table 2). Furthermore, 1 patient (2.2%) with
steroid-dependent COPD died in the perioperative period
on postoperative day 13 due to sepsis induced multiple organ
system failure.
Over half of the patients had a postoperative complication
of some sort (28/45, 62%). Additional complications not captured in the Seely classification system included unexpected
transfers to the ICU for cardiac monitoring due to atrial
fibrillation which occurred in 3/45 (6.7%). Thirty-six of the
45 patients had disposition data available. Of these patients,
88.9% (32/36) were able to be discharged home and 11.1%
(4/36) were discharged to a skilled nursing facility.
During the mean follow-up period of 53 months (range
1 week to 84 months), 13.3% (6/45) had disease recurrence
at a mean of 25 months from their operation (4 months–84
months) and 51.1% (23/45) died. Causes of death included
lung cancer recurrence in 43.5% (10/23), multiorgan system
failure in the perioperative period, stroke, amiodarone toxicity, and sepsis (1 each). Nine patients died of unknown
causes. Mean 5-year overall survival calculated by the KaplanMeier method was 52%. Medical comorbidities, clinical
stage, tumor size, any complication (grades I–V), and severe
complications (≥IIB) did not significantly influence survival
on univariate analysis.

4. Discussion
While anatomic lung resection remains the standard of care
for the treatment of NSCLC [3], octogenarians are less
likely to be offered a lobectomy than younger patients. A
Surveillance, Epidemiology and End Results (SEER) database
review of 45,912 of patients aged ≥80 demonstrated that
octogenarians were twice as likely to receive no local tumor
specific therapy (radiation or surgery) when compared to
younger patients despite a comparable rate of early stage
cancers in both groups [1]. This was even significant when
comparing octogenarians to patients aged 70–79 (47% offered
no radiation or surgery versus 28%) [1]. Another study
demonstrated the same trend and showed that as age
increases, patients undergo anatomic resection less often than
the general population and are offered radiation therapy more
often than surgery [22] despite the fact that radiation therapy
or nonanatomic lung resection remains second line therapy
for patients with operable NSCLC [3].
Even with improvement in radiation methods from
external beam radiation therapy, stereotactic body radiation
(SBRT), or stereotactic ablative radiation therapy (SABR)
[23], resection offers the best chance for local control [24].
In studies including octogenarians who are surgically or
medically inoperable, treatment decisions are a bit easier for
healthcare providers. This study sought to understand and
clarify the risks and outcomes of the gold standard therapy
(resection) within this group.
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Table 2: Complications categorized by the Seely thoracic morbidity and mortality classification system.

Grade

Patients
𝑛/45 (%)∗

Definition of complication

I

2 (4.4%)

Complication that does not
require any intervention

II

10 (22.2%)

Pharmacologic therapy or
minor intervention
required

IIIA

9 (20%)

Interventions not requiring
general anesthesia

IIIB

3 (6.7%)

Interventions requiring
general anesthesia

IV

3 (6.7%)

V

1 (2.2%)

Complication requiring
ICU support, reintubation,
single or multisystem organ
failure
Any complication leading
to death

Complication description
(𝑛/48, %)∗∗
Asymptomatic vocal cord
paralysis (1, 2.1%), urinary
retention (1, 2.1%), ileus (2,
4.2%)
Atrial fibrillation (14,
29.2%, with 10 being new
onset; 10/48, 20.8%∗∗∗ ),
esophagitis (2, 4.2%), new
home O2 (4, 8.3%), serious
electrolyte disturbance (1,
2.1%), acute kidney injury
(1, 2.1%), chyle leak (1, 2.1%)
Home with chest tube (1,
2.1%) stroke (1, 2.1%),
bleeding not requiring
transfusion (1, 2.1%),
development of a PTX
requiring drainage (1,
2.1%), chest tube duration >
5 days (10, 20.8%)
Return to OR:
postoperative hemorrhage
(2, 4.2%), fracture fixation
after fall (1, 2.1%)
MI (2, 4.2%), pneumonia
(4, 8.3%), respiratory
failure (1, 2.1%)
Multiorgan failure (1, 2.1%)

∗

Several patients had more than 1 complication and are listed in the category corresponding to the complication with the highest Seely grade.
Complications are listed individually in this column and many include multiple complications in the same patient(s).
∗∗∗
The four patients with preexisting atrial fibrillation were not included in the complication rate.
O2 : oxygen, OR: operating room, and MI: myocardial infarction.
∗∗

There has been a broad attempt across the surgical
literature to classify complications by severity in order to
standardize complication reporting. The National Cancer
Institute Common Terminology Criteria for Adverse Events
(CTCAE) is a system which grades adverse events across
multiple diverse areas of medical care on a 1–5 scale [25]. The
validated Clavien-Dindo complication classification scheme
was created for application to general surgery patients and
is graded based upon the level of intervention required to
treat the complication, a more practical system than simply
separating events into major and minor categories [19].
Seely et al. published a validated extension of the ClavienDindo system for application to the thoracic surgery patient
population [20]. Like the CTCAE, complications are graded
from I to V based on the level of intervention required to
treat the complication, with minor complications considered
grades I-II and major complications that result in significant
morbidity listed as grades III–V [20]. We used Seely grade
in order to provide us with a specific understanding of the
practical morbidity faced by octogenarian population when
undergoing lung resection.

Lower % predicted FEV1 [19], thoracotomy as approach
[9, 19], resection greater than wedge [19, 26], and mediastinal lymph node dissection [11, 16] are associated with
higher complication rates in octogenarians undergoing lung
resection. In addition, Port et al. demonstrated a statistically
significant shorter length of stay and less ICU admission rates
with VATS over thoracotomy in octogenarians undergoing
lobectomy [9]. While we did not seek to find differences
in operative approach in this study, we did not observe
a difference in complication rates between thoracotomy,
VATS, and robotic, likely due to the study size. Minimally
invasive approaches to lung resection have been shown to be
associated with fewer complications by many authors [9, 19]
and should be considered for octogenarians if appropriate.
Long-term survival after lobectomy in the elderly population is an important consideration. The calculated 5year overall survival of 52% in our series was comparable
to previous reported 5-year overall survival of 18.2–69.6%
[7–17]. Furthermore, for stage IA patients the calculated 5year overall survival rate was excellent at 78% compared
to 69.6% reported previously [9]. Univariate analysis in our

1992–1995

1981–1998

1980–1995

2000–2009

Port et al.
[9]

Hanagiri
et al. [18]

Aoki et al.
[7]

Pagni et
al. [8]

Clavien et
al. [19]

1999

1981–2006

Okami et
al. [11]

Chida et
al. [16]

2001–2008

1998–2009

Author

Umezu et
al. [10]
Okada et
al. [17]

Years of
enrollment

48

367

44

44

191

54

35

18

121

𝑁

—

—

V 77%
T

T

—

T

V = 40
T = 81

Approach (T,
V, R)

IA 14
IB 10
IIA 0
IIB 5
IIIA 5
IIIB 1

80–90 (mean
82)
≥80 (mean
81.7)

S3
L 45
P2

≥80 (mean
82)
≥80 (mean
81.8)

≥80
(median 82)

≥80

I 36
II 3
III 9

I

—

I 30
II 8
III 10

I 300
II 44
III 23

I 56%
II 10%
III 9%
IV 3%

—

—

IA 6
IB 6
IIB 1
IIIA 5

≥80 (mean,
82.1)

I
II
IIIA

IA 4
IB 5
IIB 4
IIIA 1
IIIB 4

—

≥80
(median 82)

≥80
(mean 81.2)

I 65.3%
II 25.0%
III 10.0%

Age

Pathologic
stage

Clinical stages
included

W 80
S 42
L 245

W 77
S 13
L 96
P3

W3
S3
L 43
B2
P1
chest wall 1
sleeve 1

W or S 10
L 25

S, L, W

L

Resection(s)
included
(W, S, L, B, P)

68.8%

8.4%

20%

65.9%

46%

42%, 11%

60%

50%

Complication
rate (%
overall),
severe
53.7%, 28.9%
severe
requiring
significant
intervention

Table 3: Lung resection in octogenarians: comparative data.

Comorbidity and
mediastinal
lymph node
dissection
Mediastinal LN
dissection (𝑝 =
0.004)

3.6%

Resection greater
than wedge
(𝑝 = 0.0064),
thoracotomy as
approach (𝑝 =
0.034), %
predicted FEV1
for ea 10%
decrement (𝑝 =
0.01)

—

1.4%

0

2.3%

3.7%

0%

—

—

0%

1.7%

Thoracotomy
(63%) versus
VATS (35%) 𝑝 =
0.004

—

30-day
perioperative
mortaiity (%)

Predictors of
increased
complications (𝑝
values)

35%

56.1%

44.9%

54.5%

3-year stage I
(109 patients)
56%

43%

39.8%

—

56.6%
By stage:
I = 69.6%
II = 35.6%
III = 18.2%

5-year
survival

Advanced
pathologic
stage and
comorbidity
Med LN
dissection (𝑝
= 0.022)

—

>stage I (𝑝
value not
given)

—

—

Pathologic
stage Ib or
greater (𝑝 =
0.050)

Predictors of
poor survival
(𝑝 value)
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Years of
enrollment

1981–2006

1999–2006

1981–2002

1997–2004

2004–2012

Author

Suemitsu
et al. [15]

Mun and
Kohno
[14]

Ikeda et
al. [13]

Matsuoka
et al. [12]

Current
Study

45

40

73

55

146

𝑁

W 30%
S 30%
L 40%

L

V and T

85% Muscle
sparing
PLT/VATS,
15%
standard PLT

T 59%
V 26%
R 26%

W 38 (26%)
S 17 (11.6%)
L 79 (54.1%)
B 7 (4.8%)
P 1 (0.7%)
Explorations
4 (2.7%)
W 10 (18.2%)
S 7 (12.7%)
L 37 (67.3%)
B 1 (1.8%)

Resection(s)
included
(W, S, L, B, P)

L 45 (62%)
B 2 (2.7%)
S 6 (8.2%)
W 20 (27%)

V

—

Approach (T,
V, R)

≥80 (mean
82)

80–89

80–89 (mean
83)

80–89 (mean
82.7)

≥80 (mean
82.6)

Age

IA 51%
IB 21%
IIA 11%
IIB 2.2%
IIIA 11%

—

I 60
II 10
IIIA 3

IA 32
IB 23

I 109 (74.7%)
II 14 (9.6%)
III 22 (15.1%)
IV 1 (0.7%)

Clinical stages
included

I 55 (74.3%)
II 8 (11%)
IIIA 5 (6.8%)
IIIB 4 (5.5%)
IV 1 (1.4%)
IA 52.5%
iB 35.5%
IIA 0
IIB 7.5%
IIIA 5%
IA 26%
IB 33%
IIA 8%
IIB 8%
IIIA 18%
IIIB 3%
IV 5%

I 44
II 6
III 5

I 94 (64.3%)
II 16 (11.0%)
III 31 (21.2%)
IV 5 (3.5%)

Pathologic
stage

Table 3: Continued.

62%, 17%

20%

37%

25.6%

—

Complication
rate (%
overall),
severe

—

—

—

—

—

Predictors of
increased
complications (𝑝
values)

2%

0%

4.1%

3.6%

—

30-day
perioperative
mortaiity (%)

52%

56.9%

47%

65.9%

46.8%

5-year
survival

—

—

Pathologic
stage III
compared to
II (𝑝 = 0.02)

—

—

Predictors of
poor survival
(𝑝 value)
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Years of
enrollment

1998–2004

2006–2009

1999–2005

—

2004–2007

1999–2007

1995–2004

2004–2012

Author

Nagata et al. [6]

Dales et al. [28]

Matsuo et al. [24]

Fakiris et al. [5]

Timmerman et
al. [29]

Nagata et al. [30]

Palma et al. [31]

Current Study

45

87

100–141
Gy

—

875

65

70

66

55

45

𝑁

—

48 (4)

60–66 (3)

48 (4)

54 (3)

48 (4)

Total Gy
(fractions)

≥80 (mean
82)

74

75–97

50–91
(median 89)

67–86 (76.5)

48–89 (72)

51–87

Age (median)

34.4

35.9

50.2

Stage I:
T1N0M0
T2N0M0
Stage I:
T1aN0M0
T1bN0M0
T2aN0M0
T1N0M0
T2N0M0

Stages I–IIIA

Stage I:
T1N0M0
T2N0M0
Stage I:
T1N0M0
T2N0M0
53

55

—

45.4

30

Stage I:
T1N0M0
T2N0M0

T1N0M0

Follow-up
(median months)

Clinical stages
included

—

—

62% overall,
severe 17% Seely
grade ≥IIIB

—

1.1%

—

—

88.1%

8.6% (3)
1.4% (4)
7.1% (5)
9.2% (3)

—

97.6%

—

3-year primary
tumor control
rate

—

12.7% (3)
3.6% (4)

4% (2)

Complications
(NCI-CTC
grade)

Table 4: SBRT: comparative Data.

—

—

—

—

—

—

87.2%

—

3-year local and
regional control

—

—

—

—

—

—

22.1%

—

3-year rate of
disseminated
failure

—

—

—

—

—

5 year
33.8%

3 year 48.3%

3 year
IA 72%
IB 71%

DFS

—

—

5 yr 72%
(S1a), 62%
(S1b)
5 year 52%

—

—

—

—

—

—

Predictors of
poor survival (𝑝
value)

—

3 year 76%

3 year
IA 83%
IB 72%
3 year
55.8%
(median
48.1 mo)
5 year
44.6%
(median
35.9 mo)
3 year
42.7%
(median
32.4 mo)

Overall
Survival
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study failed to reveal predictors of better survival aside from
lower pathologic stage. In this study, there was no statistically
significant survival benefit dependent on operative approach.
We have observed that many of our patients are concerned with the possible need for a nursing facility (SNF) stay
postoperatively. For patients in whom disposition data were
available (36/45), 32 (88.9%) were able to be discharged home
with 4 (11.1%) requiring discharge to a SNF. These rates are
similar to other studies which report that 6% [19] and 16.5%
[9] of octogenarians require SNF after lung resection.
Limitations to this retrospective review include patient
selection bias, lack of a control group, small size, and
variability of operative approach. The classification of complications as minor or major depending on level of intervention
required does not reflect patient quality of life and the perceived invasiveness of the intervention. Additionally, these
results may not be reproduced at other centers with different
patient selection criteria and experience. Our follow-up was
also limited at 1.7 years.
In today’s society, where an 80 year old male can expect
to live an additional 8 years (an 80-year-old female can
live another 9.3 years) [27], carefully selected medically
fit patients over 80 should be offered anatomic resection for early stage, operable NSCLC as per the NCCN
guideline recommendations [3]. We found that employing
an intervention-based, validated complication classification
scheme is helpful when discussing expected surgical outcomes within this population (octogenarians) and across
studies.
We have also shown that appropriately chosen octogenarians can undergo lobectomy with encouraging overall
survival. These data should help physicians and surgeons
understand the short-term risks and long-term survival
associated with lobectomy, provide a framework for future
comparison to SBRT or wedge resection, and allow surgeons
to counsel older patients more thoroughly.
In conclusion, while 62% of octogenarians undergoing
lobectomy had a complication, severe complications using
the Seely morbidity and mortality complication schema
occurred in only 15.6% of our study group. In addition, octogenarians deemed operable by a thoracic surgeon, regardless
of stage or surgical approach, can achieve a reasonable 5-year
survival of greater than 50%. Using this data as a foundation,
providers can accurately counsel similar patients regarding
their surgical complication risk and expected survival.
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